Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.47 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 4/20 | 0.46 |
| ▸ | FBP1 | P09467 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7035586 | 0.90 | THRB (0.52) | THRBMAPTHTTLMNANPSR1 | |
| SCHEMBL11275525 | 0.86 | THRB (0.48) | THRBMAPTHTTLMNANPSR1 | |
| SCHEMBL14035563 | 0.84 | THRB (0.44) | THRBMAPTHTTLMNANPSR1 | |
| SCHEMBL30875142 | 0.84 | THRB (0.44) | THRBMAPTHTTLMNANPSR1 | |
| SCHEMBL30730276 | 0.82 | CNR2 (0.54) | THRBMAPTHTTLMNANPSR1 | |
| SCHEMBL25174371 | 0.82 | CNR2 (0.44) | THRBMAPTHTTLMNANPSR1 | |
| SCHEMBL29990626 | 0.82 | CNR2 (0.44) | THRBMAPTHTTLMNANPSR1 | |
| SCHEMBL10367747 | 0.82 | FBP1 (0.46) | THRBMAPTHTTLMNANPSR1 | |
| SCHEMBL2937788 | 0.80 | MAPK1 (0.50) | MAPTHTTLMNANPSR1GPR55 | |
| SCHEMBL2937786 | 0.80 | MAPK1 (0.50) | MAPTHTTLMNANPSR1GPR55 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120316201-A1 | NOVEL BENZIMIDAZOLE AND IMIDAZOPYRIDINE DERIVATIVES AND USE THEREOF AS A MEDICAMENT | IPSEN PHARMA S.A.S. (FR) | 2012-12-13 | — | — | US | disclosed |
| US-8227485-B2 | Benzimidazole and imidazopyridine derivatives and use thereof as a medicament | IPSEN PHARMA S.A.S. (FR) | 2012-07-24 | — | — | US | disclosed |
| US-7816539-B2 | Derivatives of benzimidazole and imidazo-pyridine and their use as medicaments | IPSEN PHARMA S.A.S. (FR) | 2010-10-19 | — | — | US | disclosed |
| US-20090270372-A1 | NOVEL DERIVATIVES OF BENZIMIDAZOLE AND IMIDAZO-PYRIDINE AND THEIR USE AS MEDICAMENTS | SOCIETE DE CONSEILS DE RECHERCHES ET (FR) | 2009-10-29 | — | — | US | disclosed |
| US-7501524-B2 | Derivatives of benzimidazole and imidazo-pyridine and their use as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2009-03-10 | — | — | US | disclosed |
| US-7501525-B2 | Derivatives of benzimidazole and their use as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2009-03-10 | — | — | US | disclosed |
| US-20080139619-A1 | Novel derivatives of benzimidazale and imidazo-pyridine and their use as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS (S.C.R.A.S.) | 2008-06-12 | — | — | US | disclosed |
| US-7355052-B2 | Benzimidazole and imidazopyridine derivatives and use thereof as a medicament | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2008-04-08 | — | — | US | disclosed |
| US-20060281784-A1 | Novel benzimidazole and imidazopyridine derivatives and use thereof as a medicament | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (FR) | 2006-12-14 | — | — | US | disclosed |
| US-20050267147-A1 | Novel benzimidazole and imidazopyridine derivatives and use thereof as a medicament | IPSEN PHARMA S.A.S. (FR) | 2005-12-01 | — | — | US | disclosed |
| US-20050065179-A1 | Novel derivatives of benzimidazole and imidazo-pyridine and their use as medicaments | IPSEN PHARMA S.A.S. (FR) | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270372-A1 | NOVEL DERIVATIVES OF BENZIMIDAZOLE AND IMIDAZO-PYRIDINE AND THEIR USE AS MEDICAMENTS | MC4R, MC3R, MC1R | THRB 730/4885MAPT 2697/4885HTT 3285/4885 |
| US-20050065179-A1 | Novel derivatives of benzimidazole and imidazo-pyridine and their use as medicaments | MC1R, MC4R, MC3R | THRB 479/4885MAPT 1723/4885HTT 3505/4885 |
| US-20050267147-A1 | Novel benzimidazole and imidazopyridine derivatives and use thereof as a medicament | MC4R, MC1R, MC5R | THRB 374/4885MAPT 1838/4885HTT 3344/4885 |
| US-20080139619-A1 | Novel derivatives of benzimidazale and imidazo-pyridine and their use as medicaments | MC4R, MC1R, MC3R | THRB 924/4885MAPT 3226/4885HTT 3326/4885 |
| US-20120316201-A1 | NOVEL BENZIMIDAZOLE AND IMIDAZOPYRIDINE DERIVATIVES AND USE THEREOF AS A MEDICAMENT | MC4R, MC5R, MC1R | THRB 852/4885MAPT 2678/4885HTT 3446/4885 |
| US-20060281784-A1 | Novel benzimidazole and imidazopyridine derivatives and use thereof as a medicament | MC4R, MC5R, MC1R | THRB 766/4885MAPT 2729/4885HTT 3372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.